Anti cd20 engineered toxin body mt 3724

Drug Overview

The anti cd20 engineered toxin body mt 3724 is an investigational, first-in-class immunotherapy designed to treat B-cell malignancies. It represents a novel category of therapeutic agents called Engineered Toxin Bodies (ETBs), which utilize a modified bacterial toxin to kill cancer cells directly, independent of the patient’s immune system.

Developed by Molecular Templates, MT-3724 targets the CD20 antigen, a well-validated marker found on the surface of B-cells throughout most stages of development and highly expressed in many lymphomas. Unlike standard monoclonal antibodies (like rituximab) that rely on the immune system to destroy cells, MT-3724 delivers a lethal toxin payload directly into the heart of the cancer cell to shut down its protein production.

• Generic Name: MT-3724.
• Drug Class: Engineered Toxin Body (ETB) / Immunotoxin.
• Target: CD20 (B-lymphocyte antigen CD20).
• Payload: Shiga-like Toxin 1 A subunit (SLT-1A).
• Route of Administration: Intravenous (IV) infusion.
• FDA Approval Status: Discontinued/Inactive. As of 2026, MT-3724 is not FDA-approved. Clinical development was ceased by the manufacturer following Phase I/II trials due to safety concerns—primarily Capillary Leak Syndrome (CLS)—and the observation that pre-existing circulating antibodies (rituximab) could block the drug’s effectiveness.

What Is It and How Does It Work? (Mechanism of Action)

The “Forced Internalization” Strategy

Standard CD20 antibodies often stay on the cell surface. MT-3724 is engineered to “force” the CD20 receptor to be pulled inside the cell (internalization). Once inside, the toxin is released to perform its lethal function.

Molecular Level Mechanisms

1. Selective Binding: The scFv portion specifically attaches to the CD20 antigen on the B-cell.
2. Retrograde Transport: Once internalized, the drug travels through the cell’s internal transport system (endosomes to Golgi to Endoplasmic Reticulum).
3. Ribosomal Inactivation: The SLT-1A moiety acts as an N-glycosidase. It cleaves a single adenine base from the 28S RNA of the cell’s ribosome (the 60S subunit).
4. Protein Synthesis Shutdown: This cleavage permanently “breaks” the ribosome, making it impossible for the cell to manufacture proteins.
5. Direct Apoptosis: This ribotoxic stress quickly triggers apoptosis (programmed cell death). Because this mechanism is direct, it can kill cancer cells that have become resistant to traditional immune-based therapies.

FDA Approved Clinical Indications

There are currently no FDA-approved indications for MT-3724.

During its clinical testing phase, it was investigated for the following refractory conditions:

• Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL): Particularly in patients who had failed multiple prior lines of therapy.
• Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL): Evaluated in Phase I trials for patients with high-risk disease.
• Mantle Cell Lymphoma (MCL) and Follicular Lymphoma (FL): Exploratory Phase II studies.

Dosage and Administration Protocols

In clinical trials, MT-3724 required a specific “capped” dosing strategy to manage its narrow therapeutic window and safety risks.

Clinical Efficacy and Research Results

The clinical journey of MT-3724 provided significant insights into the challenges of toxin-based therapy.

• Objective Response: In serum rituximab-negative DLBCL patients, the Overall Response Rate (ORR) was approximately 41.7% (including complete and partial responses).
• The Rituximab Interference: A critical discovery was that if a patient still had rituximab in their system from a previous treatment, it would block MT-3724 from binding to CD20, rendering the drug ineffective.
• B-cell Depletion: The drug demonstrated potent, dose-dependent depletion of peripheral B-cells, proving the mechanism was biologically active in humans.

Safety Profile and Side Effects

The primary challenge with MT-3724 was its potential to damage the lining of blood vessels.

Common Side Effects (>25%):

• Peripheral Edema: Significant swelling in the limbs.
• Fatigue: General sense of exhaustion.
• Myalgia: Muscle pain (Grade 3 myalgia was the most common severe event).
• Diarrhea and Cough.

Serious Adverse Events:

• Capillary Leak Syndrome (CLS): This was the “dose-limiting toxicity.” CLS causes fluid to leak out of small blood vessels into body cavities, leading to swelling, low blood pressure, and potentially organ failure.
• Anti-Drug Antibodies (ADAs): Because the toxin is bacterial, most patients eventually developed antibodies against the drug, which could neutralize its effect over time.

Research Areas

In the field of Stem Cell and Regenerative Medicine, MT-3724 is used as a case study for “Targeted Ablation.” Researchers are studying the SLT-1A toxin to see if it can be used to “clear the niche” in the bone marrow before a Stem Cell Transplant. By using a toxin that kills cells via protein synthesis inhibition rather than DNA damage (radiation), scientists hope to develop safer ways to prepare the body for new, healthy stem cells without the long-term risks of secondary cancers.

Patient Management and Practical Recommendations

Pre-treatment Tests (Historically Required):

• Serum Rituximab Level: Mandatory screening; patients must be rituximab-negative for the drug to work.
• Baseline Weight: Used for strict dose calculation and capping.
• Liver and Kidney Function: To ensure the body can process the toxin fragments.

Precautions:

• Weight Monitoring: Patients were monitored daily for sudden weight gain, which is the first warning sign of Capillary Leak Syndrome.
• Hydration: Maintaining a balance is critical; over-hydration can worsen edema, while under-hydration can stress the kidneys.

“Do’s and Don’ts” List:

• DO report any sudden shortness of breath or “puffiness” in the face immediately.
• DO take all prescribed “pre-meds” to minimize the risk of infusion reactions.
• DON’T receive any vaccines within 28 days of treatment, as the immune system is significantly suppressed.
• DON’T ignore muscle pain (myalgia); it can be severe and require specialized pain management.

Legal Disclaimer

The information provided is for educational purposes only and does not constitute medical advice. MT-3724 is a discontinued investigational agent and is not approved by the FDA for any indication. Always consult with a qualified oncologist regarding currently available and approved treatments for lymphoma or your eligibility for active clinical trials.